Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NASDAQ:LFCR NASDAQ:ORIC NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$37.47+1.2%$23.39$13.36▼$38.59$1.21B1.46397,378 shs742,914 shsLFCRLifecore Biomedical$7.86+2.3%$7.54$4.33▼$8.85$294.04M0.64208,550 shs74,554 shsORICOric Pharmaceuticals$10.90+1.8%$10.43$3.90▼$14.67$1.06B1.631.09 million shs1.40 million shsSPRYARS Pharmaceuticals$9.41-5.5%$15.13$9.38▼$18.90$929.99M0.881.73 million shs2.31 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-0.32%+16.48%+78.59%+114.48%+27.90%LFCRLifecore Biomedical+2.13%+5.35%+4.21%+12.78%+48.26%ORICOric Pharmaceuticals-0.65%+2.00%+10.87%+18.60%+8.29%SPRYARS Pharmaceuticals-0.70%-6.92%-31.45%-32.79%-25.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$37.47+1.2%$23.39$13.36▼$38.59$1.21B1.46397,378 shs742,914 shsLFCRLifecore Biomedical$7.86+2.3%$7.54$4.33▼$8.85$294.04M0.64208,550 shs74,554 shsORICOric Pharmaceuticals$10.90+1.8%$10.43$3.90▼$14.67$1.06B1.631.09 million shs1.40 million shsSPRYARS Pharmaceuticals$9.41-5.5%$15.13$9.38▼$18.90$929.99M0.881.73 million shs2.31 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-0.32%+16.48%+78.59%+114.48%+27.90%LFCRLifecore Biomedical+2.13%+5.35%+4.21%+12.78%+48.26%ORICOric Pharmaceuticals-0.65%+2.00%+10.87%+18.60%+8.29%SPRYARS Pharmaceuticals-0.70%-6.92%-31.45%-32.79%-25.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 3.00Buy$61.5764.32% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.001.78% UpsideORICOric Pharmaceuticals 2.89Moderate Buy$17.2958.58% UpsideSPRYARS Pharmaceuticals 3.14Buy$32.50245.38% UpsideCurrent Analyst Ratings BreakdownLatest LFCR, SPRY, DNTH, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025DNTHDianthus TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $65.009/12/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$42.00 ➝ $44.009/9/2025DNTHDianthus TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$56.00 ➝ $63.009/9/2025DNTHDianthus TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$92.00 ➝ $100.009/9/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$50.00 ➝ $67.009/8/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.009/4/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.009/4/2025SPRYARS PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025LFCRLifecore BiomedicalKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight8/21/2025DNTHDianthus TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $42.008/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$20.00 ➝ $17.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$4.85M248.47N/AN/A$11.91 per share3.15LFCRLifecore Biomedical$128.87M2.28N/AN/A$0.04 per share196.50ORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/ASPRYARS Pharmaceuticals$89.15M10.43N/AN/A$2.64 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$84.97M-$3.25N/AN/AN/A-2,364.56%-34.72%-32.72%11/6/2025 (Estimated)LFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%11/12/2025 (Estimated)Latest LFCR, SPRY, DNTH, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/3/2025Q1 2026LFCRLifecore Biomedical-$0.29N/AN/AN/A$26.68 millionN/A8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/A8/7/2025Q2 2025DNTHDianthus Therapeutics-$0.86-$0.88-$0.02-$0.88$0.87 million$0.19 million8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A13.1213.12LFCRLifecore Biomedical113.762.841.77ORICOric PharmaceuticalsN/A16.1316.13SPRYARS Pharmaceuticals0.376.175.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%LFCRLifecore Biomedical83.36%ORICOric Pharmaceuticals95.05%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics8.15%LFCRLifecore Biomedical32.20%ORICOric Pharmaceuticals6.82%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8032.19 million26.86 millionOptionableLFCRLifecore Biomedical69037.41 million25.36 millionOptionableORICOric Pharmaceuticals8097.12 million91.73 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableLFCR, SPRY, DNTH, and ORIC HeadlinesRecent News About These CompaniesARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - What's Next?September 14 at 12:11 PM | marketbeat.comWoodline Partners LP Sells 518,961 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 14 at 4:11 AM | marketbeat.comOctagon Capital Advisors LP Buys Shares of 625,000 ARS Pharmaceuticals, Inc. $SPRYSeptember 11, 2025 | marketbeat.comARS Pharmaceuticals announces real-world evidence on neffy effectivenessSeptember 9, 2025 | finance.yahoo.comAlliancebernstein L.P. Has $49.35 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 9, 2025 | marketbeat.comWhat is Roth Capital's Estimate for SPRY Q3 Earnings?September 9, 2025 | marketbeat.comWhat is Roth Capital's Forecast for SPRY Q3 Earnings?September 9, 2025 | americanbankingnews.comReal-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing AnaphylaxisSeptember 8, 2025 | globenewswire.comAlyeska Investment Group L.P. Cuts Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - Should You Sell?September 8, 2025 | marketbeat.comTrexquant Investment LP Buys 44,206 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 12-Month Low - What's Next?September 8, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Now Covered by Analysts at Roth CapitalSeptember 7, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated at Roth CapitalSeptember 6, 2025 | marketbeat.comARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Cormorant Asset Management LPSeptember 6, 2025 | marketbeat.comArdsley Advisory Partners LP Takes $4.09 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 5, 2025 | marketbeat.comRoth Capital Initiates Coverage of ARS Pharmaceuticals (SPRY) with Buy RecommendationSeptember 5, 2025 | msn.comARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDASeptember 4, 2025 | msn.comARS Pharmaceuticals initiated with a Buy at Roth CapitalSeptember 4, 2025 | msn.comMPM Bioimpact LLC Acquires New Shares in ARS Pharmaceuticals, Inc. $SPRYSeptember 4, 2025 | marketbeat.comQuarry LP Takes $415,000 Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFCR, SPRY, DNTH, and ORIC Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$37.47 +0.43 (+1.16%) Closing price 04:00 PM EasternExtended Trading$38.07 +0.60 (+1.60%) As of 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Lifecore Biomedical NASDAQ:LFCR$7.86 +0.18 (+2.34%) Closing price 04:00 PM EasternExtended Trading$7.86 0.00 (-0.06%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Oric Pharmaceuticals NASDAQ:ORIC$10.90 +0.19 (+1.77%) Closing price 04:00 PM EasternExtended Trading$11.14 +0.24 (+2.20%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.ARS Pharmaceuticals NASDAQ:SPRY$9.41 -0.55 (-5.52%) Closing price 04:00 PM EasternExtended Trading$9.53 +0.12 (+1.28%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
